EUVIMEDEUVIMED entdecken
Crossref

The impact of the number of prior androgen receptor pathway inhibitors before cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer

Hisanori Taniguchi iD, Junichi Ikeda, Yuki Masuo, Hidefumi Kinoshita

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Hisanori Taniguchi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Andrology, Kansai Medical University, 2-3-1 Shinmachi, Hirakata, Osaka 573-1191, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Taxoids, Androgen Receptor Antagonists, Antineoplastic Agents. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cabazitaxel (CAZ) has been shown to prolong overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel treatment. However, the impact of the number of prior androgen receptor pathway inhibitors (ARPIs) on CAZ efficacy remains unclear. This study aimed to analyze the effectiveness of CAZ based on the number of prior ARPIs administered before CAZ treatment.

Methods

A retrospective review was conducted on mCRPC patients who received CAZ. The differences in CAZ efficacy based on the number of prior ARPIs were evaluated and prognostic factors for prostate-specific antigen (PSA) progression-free survival (PFS) and OS were analyzed.

Results

A total of 59 patients were categorized into three groups: 12 patients with no prior ARPI, 26 with one prior ARPI, and 21 with two or more prior ARPIs. The median number of CAZ cycles and relative dose intensity were 5% and 60%, respectively. No significant differences were observed in PSA response or PFS among the three groups. Although OS from the first CAZ administration did not significantly differ among the groups, the OS from mCRPC diagnosis was shorter in the group with no prior ARPI. Multivariate analysis identified a time to mCRPC diagnosis of less than 11 months and low serum hemoglobin levels before CAZ administration as significant prognostic factors of poor OS following CAZ treatment.

Conclusions

PSA response, PFS, and OS after CAZ administration did not significantly differ based on the number of prior ARPIs. CAZ efficacy appears consistent regardless of the number of prior ARPI sequences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantTaxoidsAndrogen Receptor AntagonistsAntineoplastic AgentsHumansMaleAgedRetrospective StudiesMiddle AgedAged, 80 and overProstate-Specific AntigenProgression-Free SurvivalReceptors, AndrogenNeoplasm Metastasis

Stichwörter der Autor:innen

androgen receptor pathway inhibitorcabazitaxelmetastatic castrationover-all survivalprogression free survivalresistant prostate cancer

Substanzen

cabazitaxelTaxoidsAndrogen Receptor AntagonistsProstate-Specific AntigenReceptors, AndrogenAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology and Andrology, Kansai Medical University, 2-3-1 Shinmachi, Hirakata, Osaka 573-1191, Japan.

ORCID-Profile: Hisanori Taniguchi

Zitieren

APA

Taniguchi, H., Ikeda, J., Masuo, Y., & Kinoshita, H. (2025). The impact of the number of prior androgen receptor pathway inhibitors before cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf034

Vancouver

Taniguchi H, Ikeda J, Masuo Y, Kinoshita H. The impact of the number of prior androgen receptor pathway inhibitors before cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf034

BibTeX
@article{Taniguchi2025,
  author = {Taniguchi, Hisanori and Ikeda, Junichi and Masuo, Yuki and Kinoshita, Hidefumi},
  title = {The impact of the number of prior androgen receptor pathway inhibitors before cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf034}
}
Kostenlos starten →